(NASDAQ: CADL) Candel Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Candel Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast CADL's revenue for 2027 to be $1,685,279,539, with the lowest CADL revenue forecast at $1,685,279,539, and the highest CADL revenue forecast at $1,685,279,539. On average, 1 Wall Street analysts forecast CADL's revenue for 2028 to be $4,803,321,163, with the lowest CADL revenue forecast at $4,803,321,163, and the highest CADL revenue forecast at $4,803,321,163.
In 2029, CADL is forecast to generate $15,749,403,903 in revenue, with the lowest revenue forecast at $15,749,403,903 and the highest revenue forecast at $15,749,403,903.